Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Fig. 3

Unsupervised clustering and PI3K signature score based on the RBN dataset. Heatmap depicting protein levels after unsupervised hierarchical clustering of 826 TCGA samples plus 6 baseline SU2C samples and 128 antibodies. Protein levels are indicated on a low-to-high scale (green-black-red). Annotation bars include the PAM50 intrinsic subtype classification. The PI3K score is shown in the lower panel. SU2C samples (black) are located in close proximity to triple-negative breast cancer samples from TCGA (red)

Back to article page